Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)

Completed · Not applicable · Has a placebo group

Conditions studied: Scleroderma, Systemic Sclerosis, Raynaud Phenomena, Raynaud's Disease

In brief

The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.

Key facts

Study ID
NCT02396238
Run by
Cytori Therapeutics
People needed
88
Starts
2015-05-15
Expected to finish
2018-05-22
Last updated by the study team
2018-06-04

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.